HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.

Abstract
To assess the effect of paliperidone extended-release (ER) tablets in patients with acute symptoms who had previously received risperidone. Data for this post-hoc analysis were pooled from three 6-week, double-blind, placebo-controlled trials in patients treated with paliperidone ER 3-12 mg/day or placebo. Patients had to have received risperidone for > or =4 weeks within 2 weeks of study entry. Assessments were done using the Positive and Negative Syndrome Scale, Clinical Global Impressions-Severity scale, Personal and Social Performance scale, the Simpson-Angus Scale , and adverse event (AE) reports. Altogether, 198 patients (paliperidone ER, n=142; placebo, n=56) met the established criteria. Mean (SD) duration of prior risperidone treatment and dose were 418.8 (572.8) days and 4.4 (2.5) mg/day for paliperidone ER and 527.0 (805.3) days and 4.1 (2.5) mg/day for placebo. Study completion rates were 61.3% for paliperidone ER versus 42.9% for placebo. At endpoint, paliperidone ER showed significant improvement versus placebo (P<0.05) in Positive and Negative Syndrome Scale, Clinical Global Impressions-Severity, and Personal and Social Performance scores. Mean baseline Simpson-Angus Scale scores were low, with no significant changes at endpoint in either group. AEs > or =10% with paliperidone ER versus placebo were headache (16.2 vs. 16.1%), insomnia (14.1 vs. 16.1%), and agitation (8.5 vs. 10.7%). AE-related discontinuations were 2.1% with paliperidone ER and 5.4% with placebo. In patients who had received risperidone previously but remained sufficiently symptomatic for enrollment, paliperidone ER was significantly more effective than placebo in reducing symptoms and producing functional gains.
AuthorsCarla M Canuso, Eriene A Youssef, Cynthia A Bossie, Ibrahim Turkoz, Andreas Schreiner, George M Simpson
JournalInternational clinical psychopharmacology (Int Clin Psychopharmacol) Vol. 23 Issue 4 Pg. 209-15 (Jul 2008) ISSN: 0268-1315 [Print] England
PMID18545059 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antipsychotic Agents
  • Isoxazoles
  • Pyrimidines
  • Risperidone
  • Paliperidone Palmitate
Topics
  • Adult
  • Antipsychotic Agents (adverse effects, therapeutic use)
  • Double-Blind Method
  • Female
  • Humans
  • Isoxazoles (adverse effects, therapeutic use)
  • Male
  • Paliperidone Palmitate
  • Pyrimidines (adverse effects, therapeutic use)
  • Risperidone (therapeutic use)
  • Schizophrenia (drug therapy, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: